Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9790501rdf:typepubmed:Citationlld:pubmed
pubmed-article:9790501lifeskim:mentionsumls-concept:C0039101lld:lifeskim
pubmed-article:9790501lifeskim:mentionsumls-concept:C0796358lld:lifeskim
pubmed-article:9790501lifeskim:mentionsumls-concept:C0314603lld:lifeskim
pubmed-article:9790501lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:9790501pubmed:issue3lld:pubmed
pubmed-article:9790501pubmed:dateCreated1999-5-24lld:pubmed
pubmed-article:9790501pubmed:abstractTextWe used comparative genomic hybridization (CGH) to evaluate DNA sequence copy number changes in 67 synovial sarcomas of both monophasic and biphasic histological subtypes. Changes (mean among aberrant cases: 4.7 aberrations/tumor; range: 1-17), affecting most often entire chromosomes or chromosome arms, were detected in 37 sarcomas (55%). Gains and losses were distributed equally, but different chromosomes were affected with variable frequencies. The most frequent aberrations, each detected in 9-11 of 67 tumors, were gain of 8q and gain at 12q (12q14-15 and 12q23-qter), loss of 13q21-31, and loss of 3p. Other frequent changes (in 7 or 8 cases) included gains at 2p, 1q24-31, and 17q22-qter, and losses at 3cen-q23 and 10q21. High-level amplifications were seen in 7 cases. A total of 16 regions were detected. Two of them, 8p12-qter and 21q21-qter, seen in 4 and 2 tumors, respectively, were recurrent. No aberrations specific to histological subtype were identified. However, genetic changes in the monophasic tumors were more complex and numerous (mean among aberrant cases: 5.3 aberrations/tumor; range: 1-17) than in the biphasic tumors (mean: 2.5 aberrations/tumor; range: 1-5), and high-level amplifications occurred more frequently. All but 1 of the sarcomas showing high-level amplification were of the monophasic subtype. These findings may reflect differences in the pathogenesis and biological behavior of both histological subtypes of synovial sarcoma.lld:pubmed
pubmed-article:9790501pubmed:languageenglld:pubmed
pubmed-article:9790501pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9790501pubmed:citationSubsetIMlld:pubmed
pubmed-article:9790501pubmed:statusMEDLINElld:pubmed
pubmed-article:9790501pubmed:monthNovlld:pubmed
pubmed-article:9790501pubmed:issn1045-2257lld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:AkermanMMlld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:LarssonOOlld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:KnuutilaSSlld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:ElomaaIIlld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:VirolainenMMlld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:BacchiniPPlld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:PiccoVVlld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:Asko-Seljavaa...lld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:SerraMMlld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:SzymanskaJJlld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:TarkkanenMMlld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:HuuhtanenRRlld:pubmed
pubmed-article:9790501pubmed:authorpubmed-author:SkyttingBBlld:pubmed
pubmed-article:9790501pubmed:issnTypePrintlld:pubmed
pubmed-article:9790501pubmed:volume23lld:pubmed
pubmed-article:9790501pubmed:ownerNLMlld:pubmed
pubmed-article:9790501pubmed:authorsCompleteYlld:pubmed
pubmed-article:9790501pubmed:pagination213-9lld:pubmed
pubmed-article:9790501pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:meshHeadingpubmed-meshheading:9790501-...lld:pubmed
pubmed-article:9790501pubmed:year1998lld:pubmed
pubmed-article:9790501pubmed:articleTitleGenetic imbalances in 67 synovial sarcomas evaluated by comparative genomic hybridization.lld:pubmed
pubmed-article:9790501pubmed:affiliationDepartment of Medical Genetics, Haartman Institute, University of Helsinki, Helsinki University Central Hospital, Finland.lld:pubmed
pubmed-article:9790501pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9790501pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9790501pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9790501lld:pubmed